Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adherex Technologies, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists
Histologically proven advanced and/or metastatic solid tumor of one of the following histologies:
* non-small cell lung cancer (squamous or non-squamous histology),
* gastroesophageal carcinoma (squamous or adenocarcinoma histology),
* renal cell carcinoma,
* hepatocellular carcinoma,
* adrenocortical carcinoma
Measurable disease
Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue
Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG)
You may not be if
Receipt of ADH-1 prior to this clinical study
Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry
History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months
History of tumors that have shown clinically significant evidence of active bleeding (e.g., gross hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor) within 12 weeks before study entry
Stroke, major surgery, or other major tissue injury within 30 days before study entry
History of:
* uncontrolled congestive heart failure,
* coronary artery disease, or life threatening arrhythmias;
* myocardial infarction less than 12 months prior to study entry;
